Faes Farma : Q2 2022 results in line with expectations but with a better cash flow generation
>Healthy Q2 2022 results, in line with expectations - Total Q2 2022 revenues reached € 115m (+18% y-o-y and vs +22% sales growth registered in previous quarter) but beating our estimates by 9%. By division, sales of traditional products in Spain accelerated growth this quarter (+12% y-o-y in Q2 2022 vs +3% in Q1), reflecting higher sales of Hidrofero (vitamin D) which compensated the fall in Bilaxten prices due to the end of the patent. Sales in Portugal maintained a ...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.